NAD Metabolism in Aging and Disease: Dysfunction and Intervention

衰老和疾病中的 NAD 代谢:功能障碍和干预

基本信息

  • 批准号:
    10259770
  • 负责人:
  • 金额:
    $ 34.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-09-30 至 2025-04-30
  • 项目状态:
    未结题

项目摘要

SUMMARY Aging in mammals is complex, with hallmarks including reduced propensity for stem cell self renewal, deficiencies in DNA repair, reduced responses to growth stimulating hormones and nutrients, metabolic disruption and increased susceptibilities to the onset of diseases. The origins of the deficits in self renewal, self repair, and metabolic homeostasis are central questions in the aging field. Arguably, no single factor can be identified that provides a causative effect. We have focused upon deficits in NAD+ metabolism as a potentially pleiotropic effector leading to downstream dysfunctions in cellular, tissue and organism health. Processes such as senescence, which can more readily arise from genetic factors such as defects in DNA repair genes (e.g. Werner and Bloom Syndromes) present an interesting opportunity to further investigate the role of NAD+ deficiency, given that genetically altered fibroblasts are commercially accessible as potential tools in this regard. We propose to generally characterize how aging affects NAD+ metabolism in progeroid cells, and in aged mice. Specifically, we will characterize NAD+ biosynthetic potential as well as rates of NAD+ turnover. Moreover we will assess how cells respond to pharmacologic interventions that increase NAD+ biosynthesis in order to determine if these interventions mitigate age-dependent phenotypes in these fibroblast cells. These studies will provide a deeper view of how NAD+ decline occurs in cells and tissues, and if some cells and tissues are more susceptible to this decline than others and why. A second part of the application focuses on the discovery of a novel NAD+ enhancer called dihydronicotinamide riboside (NRH), which can raise NAD+ concentrations from 3- 10 fold in mammalian cells. Preliminary data shows that NRH uses a novel mechanism of action,wherein it is converted to NMNH, independent of the known kinases Nrk1 or Nrk2, leading to biosynthesis of NAD+. In mice this compound increases NAD+ concentrations many-fold over control in most tissues. This application investigates its mechanism of action in fibroblasts and in mice to elucidate a novel biosynthetic pathway to NAD+ with translational potential for treatment of disease. Thus, in the latter part of the application, we characterize NRH effects in aged mice and ascertain if it can induce mitochondrial biogenesis. We provide studies to characterize its effects using metabolomics approaches. Finally we test NRH to treat a model of metabolic syndrome and to characterize the effect of age on disease and treatment outcomes. The objectives of the grant are accomplished via 3 specific aims: 1. To characterize NAD+ homeostasis in cells and mice as a function of age. 2. To elucidate effect and metabolic pathway of NRH in fibroblasts and mice. 3. To determine the effect of NRH on aged mice in altering NAD+ metabolism, mitochondrial biogenesis and mitigation of a model of metabolic syndrome. The accomplishment of the objectives will provide new understanding of how NAD+ is a key factor in aging and whether next generation NAD+ precursors can alter phenotypes that are hallmarks of aging.
哺乳动物的衰老是复杂的,其特征包括干细胞自我更新倾向降低,

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ANTHONY A. SAUVE其他文献

ANTHONY A. SAUVE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ANTHONY A. SAUVE', 18)}}的其他基金

Nicotinamide Riboside and NAD+: Modulation of Sirtuins and Reactive Oxygen
烟酰胺核苷和 NAD:Sirtuins 和活性氧的调节
  • 批准号:
    8670002
  • 财政年份:
    2013
  • 资助金额:
    $ 34.75万
  • 项目类别:
Nicotinamide Riboside and NAD+: Modulation of Sirtuins and Reactive Oxygen
烟酰胺核苷和 NAD:Sirtuins 和活性氧的调节
  • 批准号:
    8483680
  • 财政年份:
    2013
  • 资助金额:
    $ 34.75万
  • 项目类别:
Nicotinamide Riboside and NAD+: Modulation of Sirtuins and Reactive Oxygen
烟酰胺核苷和 NAD:Sirtuins 和活性氧的调节
  • 批准号:
    8878303
  • 财政年份:
    2013
  • 资助金额:
    $ 34.75万
  • 项目类别:
Chemical Tools to Visualize Sirtuin Activity in Cells
可视化细胞中 Sirtuin 活性的化学工具
  • 批准号:
    8386178
  • 财政年份:
    2012
  • 资助金额:
    $ 34.75万
  • 项目类别:
Chemical Tools to Visualize Sirtuin Activity in Cells
可视化细胞中 Sirtuin 活性的化学工具
  • 批准号:
    8497684
  • 财政年份:
    2012
  • 资助金额:
    $ 34.75万
  • 项目类别:
Sir2 regulation and chemical modulation
Sir2调节和化学调节
  • 批准号:
    8006734
  • 财政年份:
    2009
  • 资助金额:
    $ 34.75万
  • 项目类别:
Sir2 regulation and chemical modulation
Sir2调节和化学调节
  • 批准号:
    7020948
  • 财政年份:
    2006
  • 资助金额:
    $ 34.75万
  • 项目类别:
Sir2 regulation and chemical modulation
Sir2调节和化学调节
  • 批准号:
    7347045
  • 财政年份:
    2006
  • 资助金额:
    $ 34.75万
  • 项目类别:
Sir2 regulation and chemical modulation
Sir2调节和化学调节
  • 批准号:
    7179316
  • 财政年份:
    2006
  • 资助金额:
    $ 34.75万
  • 项目类别:
Sir2 regulation and chemical modulation
Sir2调节和化学调节
  • 批准号:
    7568219
  • 财政年份:
    2006
  • 资助金额:
    $ 34.75万
  • 项目类别:

相似海外基金

The Role of Adenosine Kinase in Mixed Diastolic Heart Failure and Alzheimer Disease
腺苷激酶在混合性舒张性心力衰竭和阿尔茨海默病中的作用
  • 批准号:
    10679989
  • 财政年份:
    2023
  • 资助金额:
    $ 34.75万
  • 项目类别:
Postnatal development of adenosine kinase in the brainstem network that controls breathing
控制呼吸的脑干网络中腺苷激酶的出生后发育
  • 批准号:
    573323-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 34.75万
  • 项目类别:
    University Undergraduate Student Research Awards
Adenosine kinase antisense gene therapy for temporal lobe epilepsy.
腺苷激酶反义基因治疗颞叶癫痫。
  • 批准号:
    9011551
  • 财政年份:
    2015
  • 资助金额:
    $ 34.75万
  • 项目类别:
The Role of Adenosine Kinase in Controlling Beta-Cell Regeneration
腺苷激酶在控制 β 细胞再生中的作用
  • 批准号:
    8888112
  • 财政年份:
    2015
  • 资助金额:
    $ 34.75万
  • 项目类别:
Interrogating the Role of Adenosine Kinase in Islet Beta-Cells
探讨腺苷激酶在胰岛β细胞中的作用
  • 批准号:
    8480250
  • 财政年份:
    2013
  • 资助金额:
    $ 34.75万
  • 项目类别:
Interrogating the Role of Adenosine Kinase in Islet Beta-Cells
探讨腺苷激酶在胰岛β细胞中的作用
  • 批准号:
    8643226
  • 财政年份:
    2013
  • 资助金额:
    $ 34.75万
  • 项目类别:
The role of adenosine kinase in atherosclerosis
腺苷激酶在动脉粥样硬化中的作用
  • 批准号:
    8583339
  • 财政年份:
    2011
  • 资助金额:
    $ 34.75万
  • 项目类别:
The role of adenosine kinase in atherosclerosis
腺苷激酶在动脉粥样硬化中的作用
  • 批准号:
    8415996
  • 财政年份:
    2011
  • 资助金额:
    $ 34.75万
  • 项目类别:
The role of adenosine kinase in atherosclerosis
腺苷激酶在动脉粥样硬化中的作用
  • 批准号:
    8764729
  • 财政年份:
    2011
  • 资助金额:
    $ 34.75万
  • 项目类别:
The role of adenosine kinase in atherosclerosis
腺苷激酶在动脉粥样硬化中的作用
  • 批准号:
    8183795
  • 财政年份:
    2011
  • 资助金额:
    $ 34.75万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了